|
(a)
|
in
the name of an intermediary that the non-registered holder deals
with in
respect of the shares, such as, among others, banks, trust companies,
securities dealers or brokers and trustees or administrators of
self-administered RRSPs, RRIFs, RESPs and similar plans;
or
|
|
(b)
|
in
the name of a depository (such as The Canadian Depository for Securities
Limited, or “CDS”) of which the intermediary is a
participant.
|
A.
|
Voting
Instruction Form. In most cases, a non-registered holder will
receive, as part of the meeting materials, a voting instruction
form. If the non-registered holder does not wish to attend and
vote at the meeting in person (or have another person attend and
vote on
the non-registered holder’s behalf), the voting instruction form must be
completed, signed and returned in accordance with the directions
on the
form. If a non-registered holder wishes to attend and vote at
the Meeting in person (or have another person attend and vote on
the
non-registered holder’s behalf), the non-registered holder must complete,
sign and return the voting instruction form in accordance with the
directions provided and a form of proxy giving the right to attend
and
vote will be forwarded to the non-registered
holder.
|
|
or
|
B.
|
Form
of Proxy. Less frequently, a non-registered holder will
receive, as part of the meeting materials, a form of proxy that has
already been signed by the intermediary (typically by a facsimile
or
stamped signature) which is restricted as to the number of shares
beneficially owned by the non-registered holder but which is otherwise
uncompleted. If the non-registered holder does not wish to
attend and vote at the Meeting in person (or have another person
attend
and vote on the non-registered holder’s behalf), the non-registered holder
must complete the form of proxy and deposit it with Computershare
Trust
Company of Canada, 100 University Avenue, 8th
Floor
Toronto, Canada, M5J 2Y1 as described above. If a
non-registered holder wishes to attend and vote at the Meeting in
person
(or have another person attend and vote on the non-registered holder’s
behalf), the non-registered holder must strike out the names of the
persons named in the proxy and insert the non-registered holder’s (or such
other person’s) name in the blank space
provided.
|
|
(a)
|
completing
and signing a proxy bearing a later date and depositing it with
Computershare Trust Company of Canada as described above;
or
|
|
(b)
|
depositing
an instrument in writing executed by the shareholder or by the
shareholder’s attorney authorized in writing: (i) at our registered office
at any time up to and including the last business day preceding the
day of
the Meeting, or any adjournment of the Meeting, at which the proxy
is to
be used, or (ii) with the chairman of the Meeting prior to the
commencement of the Meeting on the day of the Meeting or any adjournment
of the Meeting; or
|
|
(c)
|
in
any other manner permitted by law.
|
|
•
|
FOR
the election of directors;
|
|
•
|
FOR
the appointment of
auditors;
|
|
•
|
FOR
the ordinary resolution amending the 1993 Stock Option Plan and the
2003
Stock Option Plan to change the maximum number of Common Shares of
the
Corporation that may be reserved for issuance under the Plans from
a fixed
number to an amount equal to 15% of the issued and outstanding common
shares of the Corporation from time to time, as set forth in Appendix
“B”
to this Circular and described under the heading “Special Business -
Amendment to our 1993 Stock Option Plan and 2003 Stock Option Plan”;
and
|
|
•
|
FOR
the special resolution authorizing the continuance of the Corporation
out
of Ontario into the federal jurisdiction so that it is governed by
the
Canada Business Corporations
Act, as set forth in Appendix “C” to this Circular
and described under the heading “Special Business - Continuance of the
Corporation”.
|
Name
Of Director
|
Year
First
Elected/
Appointed
A
Director
|
Ownership
Or
Control
Over
Common
Shares(1)
|
J.
KEVIN BUCHI (2),
West
Chester, Pennsylvania
Senior
Vice President and Chief Financial Officer, Cephalon Inc.
(biopharmaceutical
specializing in drugs to treat and manage
neurological
diseases, sleep disorders, cancer and pain)
|
2003
|
50,000
|
DONALD
W. PATERSON(2)
(4) , Toronto, Ontario
President,
Cavandale Corporation
(corporate
consulting)
|
1991
|
125,260
|
ELLY
REISMAN, Richmond Hill, Ontario
President,
Great Gulf Group of Companies
(real
estate development)
|
1999
|
1,485,508
|
ALAN
STEIGROD(3),
Newport
Beach, CA
Managing
Director, Newport Health Care Ventures
(corporate
consulting)
|
2001
|
-
|
GRAHAM
STRACHAN(2) (3)(4)
(5), Toronto, Ontario
President,
GLS Business Development Inc.
(corporate
consulting)
|
2001
|
10,000
|
JIM
A. WRIGHT, Oakville, Ontario
President
and Chief Executive Officer of the Corporation
|
1999
|
6,112,800(6)
|
(1)
|
In
addition, as at May 31, 2005, the current directors hold, in aggregate,
options to purchase 3,039,500 common shares. These options were
granted to the directors as consideration for services rendered as
directors of the Corporation. See “Executive Compensation -
Compensation of Directors”.
|
(2)
|
Member
of the Audit Committee.
|
(3)
|
Member
of the Compensation Committee.
|
(4)
|
Member
of the Corporate Governance and Nominating
Committee.
|
(5)
|
Member
of the Environmental Committee.
|
(6)
|
Of
the 6,112,800 common
shares, 4,428,541 are owned
directly by Dr. Wright and 1,684,259 are owned by a trust for the
benefit
of Dr. Wright’s spouse.
|
Rights
of Dissenting Shareholders
185.
(1) Subject to
subsection (3) and to sections 186 and 248, if a corporation
resolves
to,
(a) amend
its articles under section 168 to add, remove or change restrictions
on
the issue, transfer or ownership of shares
|
of
a class or series of the shares of the corporation;
(b) amend
its articles under section 168 to add, remove or change any restriction
upon the business or businesses that the corporation may carry
on or upon
the powers that the corporation may
exercise;
|
(c) amalgamate
with
another corporation under sections 175 and 176;
(d) be
continued under the laws of another jurisdiction under section 181;
or
(e)
sell, lease or exchange all or substantially all its property under
subsection 184 (3),
a
holder of shares of any class or series entitled to vote on the resolution
may dissent.
(2) If
a
corporation resolves to amend its articles in a manner referred to
in
subsection 170 (1), a holder of shares of any class or series entitled
to
vote on the amendment under section 168 or 170 may dissent, except
in
respect of an amendment referred to in,
(a) clause
170 (1) (a), (b) or (e) where the articles provide that the holders
of
shares of such class or series are not entitled to dissent;
or
(b)
subsection 170 (5) or (6).
(3) A
shareholder of a corporation incorporated before the 29th day of
July,
1983 is not entitled to dissent under this section in respect of
an
amendment of the articles of the corporation to the extent that the
amendment,
(a) amends
the express terms of any provision of the articles of the corporation
to
conform to the terms of the provision as deemed to be amended by
section
277; or
(b) deletes
from the articles of the corporation all of the objects of the corporation
set out in its articles, provided that the deletion is made by the
29th
day of July, 1986.
(4) In
addition to any other right the shareholder may have, but subject
to
subsection (30), a shareholder who complies with this section is
entitled,
when the action approved by the resolution from which the shareholder
dissents becomes effective, to be paid by the corporation the fair
value
of the shares held by the shareholder in respect of which the shareholder
dissents, determined as of the close
|
of
business on the day before the resolution was adopted.
(5) A
dissenting shareholder may only claim under this section with respect to
all the shares of a class held by the dissenting shareholder on behalf
of
any one beneficial owner and registered in the name of the dissenting
shareholder.
(6) A
dissenting shareholder shall send to the corporation, at or before
any
meeting of shareholders at which a resolution referred to in subsection
(1) or (2) is to be voted on, a written objection to the resolution,
unless the corporation did not give notice to the shareholder of
the
purpose of the meeting or of the shareholder's right to
dissent.
(7) The
execution or exercise of a proxy does not constitute a written objection
for purposes of subsection (6).
(8) The
corporation shall, within ten days after the shareholders adopt the
resolution, send to each shareholder who has filed the objection
referred
to in subsection (6) notice that the resolution has been adopted,
but such
notice is not required to be sent to any shareholder who voted for
the
resolution or who has withdrawn the objection.
(9) A
notice sent under subsection (8) shall set out the rights of the
dissenting shareholder and the procedures to be followed to exercise
those
rights.
(10) A
dissenting shareholder entitled to receive notice under subsection
(8)
shall, within twenty days after receiving such notice, or, if the
shareholder does not receive such notice, within twenty days after
learning that the resolution has been adopted, send to the corporation
a
written notice containing,
(a) the
shareholder's name and address;
(b) the
number and class of shares in respect of which the shareholder dissents;
and
(c) a
demand for payment of the fair value of such shares.
(11) Not
later than the thirtieth day after the sending of a notice under
subsection (10),
a dissenting shareholder shall send the certificates representing
the
shares in respect of which the
|
shareholder
dissents to the corporation or its transfer agent.
(12) A
dissenting shareholder who fails to comply with subsections (6),
(10) and
(11) has no right to make a claim under this section.
(13) A
corporation or its transfer agent shall endorse on any share certificate
received under subsection (11) a notice that the holder is a dissenting
shareholder under this section and shall return forthwith the share
certificates to the dissenting shareholder.
(14) On
sending a notice under subsection (10), a dissenting shareholder
ceases to
have any rights as a shareholder other than the right to be paid
the fair
value of the shares as determined under this section except
where,
(a) the
dissenting shareholder withdraws notice before the corporation makes
an
offer under subsection (15);
(b) the
corporation fails to make an offer in accordance with subsection
(15) and
the dissenting shareholder withdraws notice; or
(c) the
directors
revoke a resolution to amend the articles under subsection 168 (3),
terminate an amalgamation agreement under subsection 176 (5) or an
application for continuance under subsection 181 (5), or abandon
a sale,
lease or exchange under subsection 184 (8),
in
which case the dissenting shareholder's rights are reinstated as
of the
date the dissenting shareholder sent the notice referred to in subsection
(10), and the dissenting shareholder is entitled, upon presentation
and
surrender to the corporation or its transfer agent of any certificate
representing the shares that has been endorsed in accordance with
subsection (13), to be issued a new certificate representing the
same
number of shares as the certificate so presented, without payment
of any
fee.
(15) A
corporation shall, not later than seven days after the later of the
day on
which the action approved by the resolution is effective or the day
the
corporation received the notice referred to in subsection (10), send
to
each
|
dissenting
shareholder who has sent such notice,
(a) a
written
offer to pay for the dissenting shareholder's shares in an amount
considered by the directors of the corporation to be the fair value
thereof, accompanied by a statement showing how the fair value was
determined; or
(b) if
subsection
(30) applies, a notification that it is unable lawfully to pay dissenting
shareholders for their shares.
(16) Every
offer made under subsection (15) for shares of the same class or
series
shall be on the same terms.
(17) Subject
to subsection (30), a corporation shall pay for the shares of a dissenting
shareholder within ten days after an offer made under subsection
(15) has
been accepted, but any such offer lapses if the corporation does
not
receive an acceptance thereof within thirty days after the offer
has been
made.
(18) Where
a
corporation fails to make an offer under subsection (15) or if a
dissenting shareholder fails to accept an offer, the corporation
may,
within fifty days after the action approved by the resolution is
effective
or within such further period as the court may allow, apply to the
court
to fix a fair value for the shares of any dissenting
shareholder.
(19) If
a
corporation fails to apply to the court under subsection (18), a
dissenting shareholder may apply to the court for the same purpose
within
a further period of twenty days or within such further period as
the court
may allow.
(20) A
dissenting shareholder is not required to give security for costs
in an
application made under subsection (18) or (19).
(21) If
a
corporation fails to comply with subsection (15), then the costs
of a
shareholder application under subsection (19) are to be borne by
the
corporation unless the court otherwise orders.
(22) Before
making application to the court under subsection (18) or not later
than
seven days after receiving notice of an application to the court
under
subsection (19), as the case may
|
be,
a corporation shall give notice to each dissenting shareholder who,
at the
date upon which the notice is given,
(a) has
sent to
the corporation the notice referred to in subsection (10);
and
(b) has
not
accepted an offer made by the corporation under subsection (15),
if such
an offer was made,
of
the date, place and consequences of the application and of the dissenting
shareholder's right to appear and be heard in person or by counsel,
and a
similar notice shall be given to each dissenting shareholder who,
after
the date of such first mentioned notice and before termination of
the
proceedings commenced by the application, satisfies the conditions
set out
in clauses (a) and (b) within three days after the dissenting shareholder
satisfies such conditions.
(23) All
dissenting shareholders who satisfy the conditions set out in clauses
(22)
(a) and (b) shall be deemed to be joined as parties to an application
under subsection (18) or (19) on the later of the date upon which
the
application is brought and the date upon which they satisfy the
conditions, and shall be bound by the decision rendered by the court
in
the proceedings commenced by the application.
(24) Upon
an
application to the court under subsection (18) or (19), the court
may
determine whether any other person is a dissenting shareholder who
should
be joined as a party, and the court shall fix a fair value for the
shares
of all dissenting shareholders.
(25) The
court may in its discretion appoint one or more appraisers to assist
the
court to fix a fair value for the shares of the dissenting
shareholders.
(26) The
final order of the court in the proceedings commenced by an application
under subsection (18) or (19) shall be rendered against the corporation
and in favour of each dissenting shareholder who, whether before
or after
the date of the order, complies with the conditions set out in clauses
(22) (a) and (b).
(27) The
court may in its discretion allow a reasonable rate of interest on
the
amount payable to each dissenting shareholder from the date the action
approved by the resolution is effective until the date of
payment.
|
(28) Where
subsection (30) applies, the corporation shall, within ten days after
the
pronouncement of an order under subsection (26), notify each dissenting
shareholder that it is unable lawfully to pay dissenting shareholders
for
their shares.
(29) Where
subsection (30) applies, a dissenting shareholder, by written notice
sent
to the corporation within thirty days after receiving a notice under
subsection (28), may,
(a) withdraw
a
notice of dissent, in which case the corporation is deemed to consent
to
the withdrawal and the shareholder's full rights are reinstated;
or
(b) retain
a
status as a claimant against the corporation, to be paid as soon
as the
corporation is lawfully able to do so or, in a liquidation, to be
ranked
subordinate to the rights of creditors of the corporation but in
priority
to its shareholders.
(30) A
corporation shall not make a payment to a dissenting shareholder
under
this section if there are reasonable grounds for believing
that,
(a) the
corporation is or, after the payment, would be unable to pay its
liabilities as they become due; or
(b) the
realizable value of the corporation's assets would thereby be less
than
the aggregate of its liabilities.
(31) Upon
application by a corporation that proposes to take any of the actions
referred to in subsection (1) or (2), the court may, if satisfied
that the
proposed action is not in all the circumstances one that should give
rise
to the rights arising under subsection (4), by order declare that
those
rights will not arise upon the taking of the proposed action, and
the
order may be subject to compliance upon such terms and conditions
as the
court thinks fit and, if the corporation is an offering corporation,
notice of any such application and a copy of any order made by the
court
upon such application shall be served upon the Commission.
(32) The
Commission may appoint counsel to assist the court upon the hearing
of an
application under subsection (31), if the corporation is an offering
corporation.
|
Annual
Compensation
|
Long-Term
Compensation
Awards
|
|||||
Name
and Principal Position
|
Fiscal
Year
|
Salary
($)
|
Bonus
($)
|
Other
Annual
Compensation
($)
|
Securities
Under
Options/
SARs
Granted
(#)
(4)
|
All
Other
Compensation
($)
|
Dr. Jim
A. Wright
President
and Chief
Executive
Officer
|
2005
2004
2003
|
313,586
285,000
265,000
|
95,760
102,600
110,000
|
Nil
Nil
Nil
|
228,000
570,000
417,000
|
Nil
Nil
Nil
|
Dr.
Aiping Young (1)
Chief
Operating Officer
|
2005
2004
2003
|
222,697
197,945
185,815
|
46,125
45,390
49,829
|
Nil
Nil
Nil
|
250,000
225,000
150,000
|
Nil
Nil
Nil
|
Mr.
Paul Van Damme (2)
Chief
Financial Officer
|
2005
2004
2003
|
152,654
Nil
Nil
|
35,030
Nil
Nil
|
Nil
Nil
Nil
|
202,500
Nil
Nil
|
37,000
Nil
Nil
|
Mr.
Bruce Rowlands (3)
Senior
Vice President,
Planning
and Public Affairs
|
2005
2004
2003
|
164,000
67,492
Nil
|
36,698
20,398
Nil
|
Nil
Nil
Nil
|
75,000
122,500
200,000
|
Nil
Nil
Nil
|
Mr.
Shane Ellis
Vice-President,
Legal Affairs
and
Corporate Secretary
|
2005
2004
2003
|
159,031
148,288
139,252
|
31,800
34,003
31,838
|
Nil
Nil
Nil
|
187,500
150,000
125,000
|
Nil
Nil
Nil
|
(1)
|
Dr.
Aiping Young was promoted to the position of Chief Operating Officer
on
November 20, 2003. As a result, Dr. Young’s salary for 2004
represents approximately six months compensation as Chief Technology
Officer and six months compensation as Chief Operating
Officer.
|
(2)
|
Mr.
Van Damme started with Lorus on September 7, 2004; hence, there are
no
amounts relating to Mr. Van Damme’s compensation for 2003 or
2004.
|
(3)
|
Mr.
Rowlands joined the Corporation as an employee on January 1,
2004. He had previously served as a
consultant.
|
Name
and
Principal
Position
|
Securities
Under
Options/SARs
Granted
(#)
(4)
|
%
of Total
Options/SARs
Granted
to
Employees
in
Financial
Year
(%)
|
Exercise
or
Base
Price
($/Security)
|
Market
Value
of
Securities
Underlying
Options/SARs
on
the
Date
of Grant
($/Security)
|
Expiration
Date
|
Dr.
Jim A. Wright
President
and Chief
Executive
Officer
|
228,000
(2)
|
7.27%
|
0.78
|
0.78
|
21-Jul-2014
|
Dr.
Aiping Young
Chief
Operating Officer
|
75,000
(1)
175,000(2)
|
2.39%
5.58%
|
0.78
0.78
|
0.78
0.78
|
21-Jul-2014
21-Jul-2014
|
Mr.
Paul Van Damme
Chief
Financial Officer
|
127,500
(2)
75,000
(3)
|
4.06%
2.39%
|
0.74
0.74
|
0.74
0.74
|
6-Oct-2014
6-Oct-2014
|
Mr.
Bruce Rowlands
Senior
Vice-President,
Planning
and Public Affairs
|
75,000
(1)
|
2.39%
|
0.78
|
0.78
|
21-Jul-2014
|
Mr.
Shane Ellis
Vice-President,
Legal
Affairs
and Corporate
Secretary
|
75,000
(1)
62,500
(2)
50,000
(2)
|
2.39%
1.99%
1.59%
|
0.78
0.78
0.72
|
0.78
0.78
0.72
|
21-Jul-2014
21-July-2014
17-Nov-2014
|
(1)
|
These
options were granted on July 22, 2004 in respect of corporate and
personal
performance during the year ended May 31, 2005. The options vest
on the
basis of 50% on the first anniversary and 25% on the second and third
anniversaries of the date of granting. The exercise price of
all the $0.78 options was the closing price of our common shares
on the
TSX on July 21, 2004.
|
(2)
|
These
options are incentive options granted to certain Named Executive
Officers
to purchase common shares of the Corporation. The options vest
immediately upon the attainment of specific undertakings; failing
to
achieve the undertakings will result in forfeiture on the specified
deadline.
|
(3)
|
These
options were granted in recognition of Mr. Van Damme’s commencement of
employment with the Corporation and vested
immediately.
|
(4)
|
Options
granted are net of forfeitures.
|
Name
|
Securities
Acquired
on
Exercise
(#)
|
Aggregate
Value
Realized
($)
|
Unexercised
Options/SARs
at
May
31, 2005
(#)
Exercisable/
Unexercisable
|
Value
of
Unexercised
in-the-Money
Options/SARs
at
May
31, 2005 ($)
Exercisable/
Unexercisable
|
Dr.
Jim A. Wright
President
and Chief Executive Officer
|
Nil
|
Nil
|
1,295,750/179,250
|
35,408/3,803
|
Dr.
Aiping Young
Chief
Operating Officer
|
Nil
|
Nil
|
807,047/131,250
|
28,500/0
|
Mr.
Paul Van Damme
Chief
Financial Officer
|
Nil
|
Nil
|
202,500/0
|
0/0
|
Mr.
Bruce Rowlands
Senior
Vice-President, Planning and
Public
Affairs
|
Nil
|
Nil
|
247,500/75,000
|
21,250/0
|
Mr.
Shane Ellis
Vice-President,
Legal Affairs and
Corporate
Secretary
|
Nil
|
Nil
|
792,506/131,250
|
48,934/0
|
|
•
|
Virulizin
clinical study - Successfully progress the Virulizin Phase III clinical
trial to be on target to achieve last patient last visit by July,
2005,
including conduct of clinical audits and database tracking for closure
of
the clinical study, so that data can be expeditiously analyzed for
NDA
submission;
|
|
•
|
Antisense
clinical studies - Complete the Phase II clinical trial for GTI-2040
in
renal cell carcinoma, finalize the clinical research report for this
Phase
II clinical trial, and prepare a detailed protocol for a Phase II/III
registration clinical trial with GTI-2040 in combination with a
cytokine;
|
|
•
|
Manufacturing
- Successfully transition the Virulizin manufacturing process to
Lorus’
commercial manufacturing partner, by demonstrating the ability to
successfully prepare a 96 litre batch of Virulizin using the optimized
consolidated process to obtain material that meets FDA approval
criteria;
|
|
•
|
Partnership
- Obtain a commitment for a partnership agreement with one of Lorus’
technologies: Virulizin, GTI-2040, GTI-2501, small molecule,
tumor suppressor; and,
|
|
•
|
Finance
- Have at least 18 months of operating
cash.
|
Plan
Category
|
#
of Shares to be
issued
upon
exercise
of
outstanding
options
|
Weighted-average
exercise
price of
outstanding
options
|
#
of Shares
remaining
available
for
future issuance
under
the Equity
Compensation
Plans
|
|||
Plans
approved by Shareholders(1)
|
8,034,750
|
$0.96
|
4,758,924
|
|||
Plans
not approved by Shareholders
|
-
|
-
|
-
|
|||
Total
|
8,034,750
|
$0.96
|
4,758,924
|
(1)
|
This
includes options granted and reserved for issuance pursuant to our
1993
Stock Option Plan, 2003 Stock Option Plan, and our Alternate Compensation
Plan.
|
(signed)
SHANE A. ELLIS
|
|
July
29, 2005
|
Vice
President of Legal Affairs and
|
Corporate
Secretary
|
TSX
Guidelines
|
Comments
|
|
(1)
|
The
board should explicitly assume responsibility for stewardship of
the
Corporation, and as part of the overall stewardship responsibility,
should
assume responsibility for the following matters:
|
The
Board of Directors has assumed responsibility for the stewardship
of the
Corporation by overseeing the management and operations of the
business
and supervising management, which is responsible for the day-to-day
conduct of the business.
The
Board Policy Manual and the terms of reference of the Board of
Directors,
committees and individual directors set out the purpose, procedure
and
organization, and responsibilities and duties of the Board and
its
committees.
|
(a)
|
adoption
of a strategic planning process;
|
The
Board has assumed
responsibility for ensuring there are long-term goals and strategies
in
place for the Corporation. The Corporation’s goals and
strategies are prepared and reviewed together by management and
the Board
on an annual basis and are a primary component of the Board’s annual
agenda.
|
The
Board as a whole participates in discussions on corporate strategy
and,
where appropriate, approves the strategies and implementation plans
recommended by management.
|
||
Implementation
of the strategic plan is the responsibility of management. The
Board provides guidance but does not become involved in day-to-day
matters.
|
||
Management
reports to the Board on the Corporation’s progress in achieving the
strategic objectives set out in the strategic
plan.
|
TSX
Guidelines
|
Comments
|
|
(b)
|
the
identification of the principal risks of the Corporation’s business and
ensuring the implementation of appropriate systems to manage these
risks;
|
The
Board, through its committees and as a whole, believes that it understands
the specific risks of the Corporation’s business. The Corporate Governance
and Nominating Committee has established a review process to assign
responsibility for principal risks among the Board as a whole and
the
committees of the Board.
Management
reports to the Board or committees of the Board on a regular basis
on the
status of key risk areas.
The
Board reviews and approves the Corporation’s annual capital and operating
budgets. The Audit Committee reviews performance against
budgets on a quarterly basis.
|
(c)
|
succession
planning, including appointing, training and monitoring senior
management;
|
The
Human Resources and Compensation Committee periodically reviews the
Corporation’s organizational plan and structure and annually reviews the
senior executive succession plan, recommending the same to the Board
for
approval.
The
Corporation’s Human Resources and Compensation Committee, composed of
unrelated directors, monitors the performance of senior management
and
reports to the whole Board.
|
(d)
|
a
communications policy for the corporation; and
|
A
formal disclosure and communications policy has been developed which
includes the assignment of responsibility for disclosure to a corporate
communications team. It is intended that this team may consult with
professional advisors and/or Board members as appropriate in the
circumstances.
The
Corporation has established a policy addressing employee and insider
trading. Among other things, the policy requires that the
Corporation set trading blackouts for employees and directors in
advance
of news releases and/or in other circumstances as
appropriate.
|
(e)
|
the
integrity of the corporation’s internal control and management information
systems.
|
The
Board has appointed an Audit Committee composed of independent directors
that reviews compliance of financial reporting with accounting principles
and appropriate internal controls. The Audit Committee meets
quarterly with management and the external auditors to review financial
statements, internal controls and other matters. The Audit
Committee reports to the Board prior to the approval of the quarterly
and
annual financial statements.
|
TSX
Guidelines
|
Comments
|
|
(2)
|
A
majority of directors should be “unrelated” (independent of management and
free from any business or other relationship which could, or could
reasonably be perceived to, materially interfere with the director’s
ability to act with a view to the best interests of the Corporation
other
than interests and relationships arising from
shareholding).
|
The
Corporation’s Board is constituted of a majority of unrelated
directors. The only related Board member is Dr. Jim Wright, the
Corporation’s President and Chief Executive Officer. The other
Board members are unrelated. The Corporation does not have any
significant shareholders (i.e. holders of 10% or greater of the
outstanding common shares of the Corporation).
|
(3)
|
The
board has responsibility for applying the definition of “unrelated
director” to each individual director and for disclosing annually the
analysis of the application of the principles supporting this definition
and whether the board has a majority of unrelated
directors.
|
Dr.
Jim Wright is a related Board member, as he is the President and
Chief
Executive Officer of the Corporation. The Board has determined
that Dr. Wright will be the only director who is a related
director.
The
remainder of the present directors and nominees for election to the
Board
at the Meeting are unrelated. Additional disclosure on Board
members, with respect to their business experience and backgrounds,
can be
found in our annual information form and in our annual
report.
|
(4)
|
The
board should appoint a committee of directors composed exclusively
of
outside, i.e., non-management directors, a majority of whom are unrelated
directors, with the responsibility for proposing new nominees to
the board
and for assessing directors on an ongoing basis.
|
The
Corporation has established a Corporate Governance and Nominating
Committee, which as part of its mandate, has the responsibility of
recommending qualified candidates for the Board and annually reviewing
the
effectiveness of the Board and individual members of the
Board.
All
members of the Corporate Governance and Nominating Committee are
unrelated
directors.
|
(5)
|
The
board should implement a process to be carried out by an appropriate
committee, for assessing the effectiveness of the board as a whole,
the
committees of the board and the contribution of individual
directors.
|
The
Corporate Governance and Nominating Committee has been mandated to
ensure
that the contribution of Board members, committees of the Board and
the
Board as a whole is reviewed on an annual basis. A process is
being established which will involve questionnaires to be completed
by
individual board members. The Corporate Governance and
Nominating Committee will review the findings of the questionnaires
and
will report the results regarding the Board members and Board committees
to the Board. Additionally, the Corporate Governance and
Nominating Committee monitors the quality of the relationship between
management and the Board in order to recommend ways to improve that
relationship.
|
TSX
Guidelines
|
Comments
|
|
(6)
|
The
company, as an integral element of the process for appointing new
directors, should provide an orientation and education program for
new
directors.
|
The
Corporation is developing a director’s orientation manual containing
salient information about the Corporation including the operation
of the
Board and the committees of the Board. Additionally, the
Corporation provides new directors the opportunity to meet senior
management both prior and subsequent to joining the Board.
Most
Board meetings are held at the Corporation’s premises to give additional
insight into the business.
The
President and Chief Executive Officer, in conjunction with the Chairman
of
the Board, also periodically selects special educational or informational
topics for presentation and discussion at Board meetings, which deal
with
the business and regulatory environment in which the Corporation
operates,
and the biopharmaceutical industry generally.
|
(7)
|
The
board should examine its size, and, with a view to determining the
impact
upon effectiveness, undertake where appropriate, a program to reduce
the
number of directors to a number which facilitates more effective
decision-making.
|
A
Board must have enough directors to carry out its duties efficiently,
while presenting a diversity of views and independence. The
Board has considered whether the current size of the Board permits
such
diversity and allows sufficient resources to carry out the duties
of the
Board. The number of directors fixed for the coming year is
six. From time to time the Board assesses the number of
directors for Board effectiveness.
|
(8)
|
The
board should review the adequacy and form of compensation of directors
and
ensure the compensation realistically reflects the risks and
responsibilities involved in being an effective director.
|
It
is in the mandate of the Human Resources and Compensation Committee
to
review the appropriateness and adequacy of directors’ compensation on an
annual basis.
|
(9)
|
Committees
of the board should generally be composed of outside directors, a
majority
of whom are unrelated directors, although some board committees,
such as
the executive committee, may include one or more inside
directors.
|
All
Board committees are composed solely of non-management
directors.
|
TSX
Guidelines
|
Comments
|
|
(10)
|
The
board should expressly assume responsibility for, or assign to a
committee
of directors the general responsibility for, developing the company’s
approach to governance issues. The committee would, amongst
other things, be responsible for the company’s response to these
governance guidelines.
|
The
Corporate Governance and Nominating Committee is made up of two outside
directors, Graham Strachan and Donald Paterson. The committee met
fifteen
times in fiscal 2005. The committee is responsible for and makes
recommendations to the Board concerning the governance of the
Corporation. Included in the Corporate Governance and
Nominating Committee mandate is the responsibility to:
1. develop
the Corporation’s approach to corporate governance issues;
2. monitor
the application of the Corporation’s governance principles and report to
the Board on a regular basis; and
3. review
the mandates of the various Board Committees and recommend
changes.
The
committee has developed a code of ethics for the principal and senior
officers of the Corporation. Such code is aimed at creating written
standards that are reasonably designed to deter wrongdoing and to
promote:
• honest
and ethical conduct, including the ethical handling of actual or
apparent
conflicts of interest between personal and professional
relationships;
|
• full,
fair, accurate, timely and understandable disclosure in public
communications and in reports and documents that are filed with or
submitted to the all security regulatory authorities;
• compliance
with applicable laws, rules and regulations;
• the
prompt internal reporting of code violations to such person or persons
identified in the code; and
• accountability
for adherence to the code.
|
||
The
code also contains a prohibition on taking any action to fraudulently
influence, coerce, manipulate or mislead the auditors of the Corporation
and prohibit retaliation against “Whistle Blowers” (employees who provide
information or assist in a government or supervisory investigation
of the
Corporation).
|
TSX
Guidelines
|
Comments
|
|
(11)
|
The
board of directors, together with the CEO, should develop position
descriptions for the board and for the CEO, involving the definition
of
the limits to management’s responsibilities. The board should approve or
develop the corporate objectives, which the CEO is responsible for
meeting.
|
Position
descriptions are being developed for all senior management including
the
President and Chief Executive Officer. Mandates have been established
for
all committees of the Board. It is intended that the limits to
management’s authority, and the circumstances where Board approval is
required will be clearly defined.
The
Corporation sets and approves corporate objectives as part of its
annual
budgeting process. These objectives, together with the
Corporation’s strategic plan, comprise the principal mandate of the
President and Chief Executive Officer. The President and Chief
Executive Officer’s objectives also include the general mandate to
maximize shareholder value.
The
corporate objectives are reviewed quarterly by the Board and the
President
and Chief Executive Officer’s performance is review based on performance
against these objectives.
|
(12)
|
The
board should have in place appropriate structures and procedures
to ensure
that the board can function independently of management. An appropriate
structure would be to (i) appoint a Chair of the board who is not
a member
of management with responsibility to ensure that the board discharges
its
responsibilities or (ii) adopt alternate means such as assigning
this
responsibility to a committee of the board or to a director, sometimes
referred to as the “lead director”.
Appropriate
procedures may involve the board meeting on a regular basis without
management present or may involve expressly assigning responsibility
for
administering the board’s relationship to management to a committee of the
board.
|
The
Chair of the Board is not a member of management and together with
the
Corporate Governance and Nominating Committee has the responsibility
to
ensure the Board discharges its responsibilities. The Chair of
the Board maintains open communication with all directors. The
Board meets independent of management
quarterly.
|
TSX
Guidelines
|
Comments
|
|
(13)
|
The
Audit Committee should be composed only of outside directors. The
roles
and responsibilities of the Audit Committee should be specifically
defined
so as to provide appropriate guidance to Audit Committee members
as to
their duties. The Audit Committee should have direct communication
channels with the internal and the external auditors to discuss and
review
specific issues as appropriate.
|
The
Audit Committee, which is composed entirely of outside directors,
is
responsible for reviewing audit functions and financial statements,
and
reviewing and recommending for approval for release to the Board
all
public disclosure information such as financial statements, quarterly
reports, financial news releases, annual information forms, management’s
discussion and analysis and prospectuses. The Audit committee includes
a
director, J. Kevin Buchi, with financial expertise.
|
The
Audit Committee duties should include oversight responsibility for
management reporting on internal control. While it is management’s
responsibility to design and implement an effective system of internal
control, it is the responsibility of the Audit Committee to ensure
that
management has done so.
|
The
Audit Committee ensures that the auditor reports to the Audit
Committee on (i) all critical accounting policies, (ii) alternative
treatments of financial information that have been discussed with
management and (iii) other material written communications with
management.
The
Audit Committee also ensures that management has effective internal
control systems, and an appropriate relationship with the external
auditors and meets regularly with the external auditors, without
management present.
|
|
(14)
|
The
board of directors should implement a system to enable an individual
director to engage an outside advisor, at the expense of the company
in
appropriate circumstances. The engagement of the outside
advisor should be subject to the approval of an appropriate committee
of
the board.
|
Individual
directors may engage outside advisers at the Corporation’s expense, where
appropriate, with the prior approval of the Corporate Governance
and
Nominating Committee.
|
|
(i)
|
the
number of shares issuable to insiders, at any time, under the Plan
and all
other security-based compensation arrangements, cannot exceed 10%
of
issued and outstanding shares; and
|
|
(ii)
|
the
number of shares issued to insiders, within any one year period,
under the
Plan and all other security-based compensation arrangements, cannot
exceed
10% of issued and outstanding shares;
and
|
|
(i)
|
the
number of shares issuable to insiders, at any time, under the Plan
and all
other security-based compensation arrangements, cannot exceed 10%
of
issued and outstanding shares; and
|
|
(ii)
|
the
number of shares issued to insiders, within any one year period,
under the
Plan and all other security-based compensation arrangements, cannot
exceed
10% of issued and outstanding
shares.
|